These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30942465)

  • 41. Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer.
    Razaviyan J; Hadavi R; Tavakoli R; Kamani F; Paknejad M; Mohammadi-Yeganeh S
    Appl Biochem Biotechnol; 2018 Dec; 186(4):1074-1089. PubMed ID: 29862445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
    Abdel-Sater F; Najar M; Fayyad-Kazan H
    J Cell Physiol; 2020 Jun; 235(6):5204-5212. PubMed ID: 31736084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer.
    Tang Q; Ouyang H; He D; Yu C; Tang G
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2800-2809. PubMed ID: 31284781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential Role of miRNA in Metastatic Cascade of Triple-Negative Breast Cancer.
    Balkrishna A; Mittal R; Arya V
    Curr Cancer Drug Targets; 2021; 21(2):153-162. PubMed ID: 33155912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
    Xu X; Zhang Y; Jasper J; Lykken E; Alexander PB; Markowitz GJ; McDonnell DP; Li QJ; Wang XF
    Oncotarget; 2016 Apr; 7(15):20381-94. PubMed ID: 26967387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
    Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
    Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
    Reyes ME; Fujii T; Branstetter D; Krishnamurthy S; Masuda H; Wang X; Reuben JM; Woodward WA; Edwards BJ; Hortobagyi GN; Tripathy D; Dougall WC; Eckhardt BL; Ueno NT
    Breast Cancer Res Treat; 2017 Jul; 164(1):57-67. PubMed ID: 28417335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
    Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
    J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
    Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
    Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated miR-301a expression indicates a poor prognosis for breast cancer patients.
    Zheng JZ; Huang YN; Yao L; Liu YR; Liu S; Hu X; Liu ZB; Shao ZM
    Sci Rep; 2018 Feb; 8(1):2225. PubMed ID: 29396508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNAs-mediated cell fate in triple negative breast cancers.
    Sui X; Wang X; Han W; Li D; Xu Y; Lou F; Zhou J; Gu X; Zhu J; Zhang C; Pan H
    Cancer Lett; 2015 May; 361(1):8-12. PubMed ID: 25748387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis.
    Lu Y; Yang G; Xiao Y; Zhang T; Su F; Chang R; Ling X; Bai Y
    Breast Cancer; 2020 Sep; 27(5):903-911. PubMed ID: 32338339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down Regulated Expression Levels of miR-27b and miR-451a as a Potential Biomarker for Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy.
    Abdul Aziz AA; Md Salleh MS; Yahya MM; Zakaria AD; Ankathil R
    Asian Pac J Cancer Prev; 2022 Mar; 23(3):1053-1059. PubMed ID: 35345380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.
    Song D; Yue L; Zhang J; Ma S; Zhao W; Guo F; Fan Y; Yang H; Liu Q; Zhang D; Xia Z; Qin P; Jia J; Yue M; Yu J; Zheng S; Yang F; Wang J
    Cancer Biol Ther; 2016 Jun; 17(6):635-47. PubMed ID: 27260686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
    Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
    Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.
    Toda H; Kurozumi S; Kijima Y; Idichi T; Shinden Y; Yamada Y; Arai T; Maemura K; Fujii T; Horiguchi J; Natsugoe S; Seki N
    J Hum Genet; 2018 Dec; 63(12):1197-1210. PubMed ID: 30228364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma.
    Wang ZX; Deng TX; Ma Z
    J Cell Biochem; 2019 Oct; 120(10):16416-16426. PubMed ID: 31297864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis.
    Lu M; Kong X; Wang H; Huang G; Ye C; He Z
    Oncotarget; 2017 Jan; 8(5):8775-8784. PubMed ID: 28060739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
    Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R
    Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.